• Tuesday, Oct 04, 2022
  • Last Update : 10:24 am

J&J files for US clearance for Covid-19 vaccine booster doses

  • Published at 04:22 am October 6th, 2021
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only"and a medical syringe are seen in front of a displayed Johnson & Johnson
Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only"and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020 Reuters

Last month FDA authorized booster shots of Pfizer’s vaccine

Johnson & Johnson said on Tuesday it had submitted data to the US Food and Drug Administration for emergency use authorization of a booster shot of its Covid-19 vaccine in people aged 18 and older.

J&J said its submission includes data from a late-stage study that found a booster given 56 days after the primary dose provided 94% protection against symptomatic Covid-19 in the United States and 100% protection against severe disease, at least 14 days after the booster shot.

While scientists are divided over the need for booster shots when so many people in the United States and other countries remain unvaccinated, the Biden administration announced the push for an extra dose in August to shore up protection against the highly transmissible Delta variant.

J&J's filing comes after the FDA last week scheduled an October 15 meeting of its expert advisory committee to discuss whether to authorize a second shot of the company's single-dose vaccine.

Shares of the healthcare conglomerate rose nearly 1% in trading before the opening bell.

The FDA has already authorized a booster dose of the vaccine developed by Pfizer Inc and partner BioNTech for 65-year olds and older, people at high risk of severe disease and others who are regularly exposed to the virus.


Also Read- Pfizer-BioNTech Covid-19 vaccine effectiveness drops after 6 months, study shows


Pfizer had also asked the FDA to expand its vaccine approval to include boosters for all people aged 16 and older, but the regulator decided to limit their use saying evidence showed they were helpful to older people and those at high risk.

Rival vaccine maker Moderna also submitted an application seeking authorization for a booster shot of its two-dose vaccine last month, and an FDA panel will hold a meeting on October 14 to discuss the extra dose.

J&J said it plans to submit the data to other regulators, the World Health Organization and National Immunization Technical Advisory Groups to inform decision-making on local vaccine administration strategies, as needed.

About 15 million Americans aged 18 and older have received one dose of J&J's vaccine, according to latest data from the Centers for Disease Control and Prevention.

50
Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail